{"id":744873,"date":"2014-12-10T09:30:00","date_gmt":"2014-12-10T09:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/"},"modified":"2023-03-22T00:04:47","modified_gmt":"2023-03-22T04:04:47","slug":"merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/","title":{"rendered":"Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the appointment of Dr. Julie Gerberding, 59, as<br \/>\n      executive vice president for strategic communications, global public<br \/>\n      policy and population health, effective Dec. 15. In this newly created<br \/>\n      Executive Committee position, Gerberding, who most recently served as<br \/>\n      president of Merck Vaccines, will be responsible for Merck\u2019s global<br \/>\n      public policy, corporate responsibility and communications functions, as<br \/>\n      well as the Merck Foundation and the Merck for Mothers program.<br \/>\n      Gerberding will also lead new partnership initiatives that accelerate<br \/>\n      Merck\u2019s ability to contribute to improved population health, a measure<br \/>\n      of impact that is increasingly valued by governments and other global<br \/>\n      health organizations.\n    <\/p>\n<p>\n      &#8220;Julie has been instrumental in making Merck\u2019s vaccines more accessible<br \/>\n      and affordable, particularly in emerging markets and many of the world\u2019s<br \/>\n      most resource-limited countries,\u201d said Kenneth C. Frazier, chairman and<br \/>\n      chief executive officer, Merck. \u201cJulie\u2019s leadership of our vaccines<br \/>\n      business and her exceptional track record in both the public and private<br \/>\n      sectors make her ideally suited to lead these areas and to advance our<br \/>\n      engagement with organizations around the world that, like Merck, are<br \/>\n      working to advance population health.\u201d\n    <\/p>\n<p>\n      Gerberding joined Merck as president of Merck Vaccines in January 2010.<br \/>\n      Since then, Merck\u2019s vaccines are reaching more people than ever, and<br \/>\n      Merck became the global leader in the vaccine market based on sales. In<br \/>\n      addition, the Sanofi Pasteur MSD joint venture in Europe, Merck\u2019s<br \/>\n      European vaccine business for which Gerberding is the Board co-chair,<br \/>\n      has improved in both population reach and financial performance. She<br \/>\n      also helped lead the successful launch in India of the Merck Wellcome<br \/>\n      Trust non-profit joint venture for vaccine development, the MSD Wellcome<br \/>\n      Trust Hilleman Laboratories.\n    <\/p>\n<p>\n      Prior to joining Merck, Gerberding served as director of the U.S.<br \/>\n      Centers for Disease Control and Prevention (CDC) from 2002-2009 and<br \/>\n      before that served as director of the Division of Healthcare Quality<br \/>\n      Promotion. Before joining the CDC, Gerberding was a tenured faculty<br \/>\n      member in Infectious Diseases at the University of California at San<br \/>\n      Francisco (UCSF). She continues as an Adjunct Associate Clinical<br \/>\n      Professor of Medicine at UCSF.\n    <\/p>\n<p>\n      &#8220;People across health systems everywhere are realizing that no single<br \/>\n      organization can solve the complex challenges we face. Whether<br \/>\n      containing the current Ebola outbreak, increasing vaccination rates or<br \/>\n      improving the overall health of people in communities, partnerships<br \/>\n      between public and private sector organizations are essential,\u201d Dr.<br \/>\n      Gerberding said. \u201cMerck has a unique role and a responsibility to<br \/>\n      contribute, and I welcome this opportunity to lead teams of experts who<br \/>\n      will help us achieve our mission of saving lives and improving health<br \/>\n      around the world.\u201d\n    <\/p>\n<p>\n      Jacques Cholat, currently vice president, global vaccines marketing and<br \/>\n      commercial operations, has been appointed interim president of Merck<br \/>\n      Vaccines. \u201cJacques\u2019 leadership has enabled Merck to significantly expand<br \/>\n      the global reach of its global vaccines business,\u201d Mr. Frazier said.<br \/>\n      Cholat joined Merck from Sanofi Pasteur in November 2011, where he had<br \/>\n      served as vice president of Sanofi Pasteur international commercial<br \/>\n      operations since July 2002.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50999941&#038;newsitemid=20141210005127&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=065d843126261a13b06ec45d20ad1d12\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2Fmerck&#038;esheet=50999941&#038;newsitemid=20141210005127&#038;lan=en-US&#038;anchor=Twitter&#038;index=2&#038;md5=1303a528a5d2d01b65482c99f61bda05\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50999941&#038;newsitemid=20141210005127&#038;lan=en-US&#038;anchor=Facebook&#038;index=3&#038;md5=9eb1f92e713def3b31e6457b7adf93ff\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50999941&#038;newsitemid=20141210005127&#038;lan=en-US&#038;anchor=YouTube&#038;index=4&#038;md5=1722507147017eee1aab170aff63041c\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50999941&#038;newsitemid=20141210005127&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=5&#038;md5=7d8a0d4967fcc018477a8414a4dd4b84\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20141210005127r1&#038;sid=hq1sc1&#038;distro=nx&#038;lang=en\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Steven Cragle, 908-740-1801<br \/>Lainie Keller,        908-236-5036<br \/>or<br \/>Investors:<br \/>Joe Romanelli, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Dr. Julie Gerberding, 59, as executive vice president for strategic communications, global public policy and population health, effective Dec. 15. In this newly created Executive Committee position, Gerberding, who most recently served as president of Merck Vaccines, will be responsible for Merck\u2019s global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Gerberding will also lead new partnership initiatives that accelerate Merck\u2019s ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations. &#8220;Julie has been instrumental in making Merck\u2019s vaccines more accessible and affordable, particularly in emerging markets and many of the world\u2019s most resource-limited countries,\u201d said Kenneth C. Frazier, chairman and<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744873","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Dr. Julie Gerberding, 59, as executive vice president for strategic communications, global public policy and population health, effective Dec. 15. In this newly created Executive Committee position, Gerberding, who most recently served as president of Merck Vaccines, will be responsible for Merck\u2019s global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Gerberding will also lead new partnership initiatives that accelerate Merck\u2019s ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations. &quot;Julie has been instrumental in making Merck\u2019s vaccines more accessible and affordable, particularly in emerging markets and many of the world\u2019s most resource-limited countries,\u201d said Kenneth C. Frazier, chairman and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:47+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141210005127r1&sid=hq1sc1&distro=nx&lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\\\/\",\"name\":\"Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20141210005127r1&sid=hq1sc1&distro=nx&lang=en\",\"datePublished\":\"2014-12-10T09:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20141210005127r1&sid=hq1sc1&distro=nx&lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20141210005127r1&sid=hq1sc1&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Dr. Julie Gerberding, 59, as executive vice president for strategic communications, global public policy and population health, effective Dec. 15. In this newly created Executive Committee position, Gerberding, who most recently served as president of Merck Vaccines, will be responsible for Merck\u2019s global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Gerberding will also lead new partnership initiatives that accelerate Merck\u2019s ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations. \"Julie has been instrumental in making Merck\u2019s vaccines more accessible and affordable, particularly in emerging markets and many of the world\u2019s most resource-limited countries,\u201d said Kenneth C. Frazier, chairman and","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:47+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141210005127r1&sid=hq1sc1&distro=nx&lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/","name":"Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141210005127r1&sid=hq1sc1&distro=nx&lang=en","datePublished":"2014-12-10T09:30:00+00:00","dateModified":"2023-03-22T04:04:47+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141210005127r1&sid=hq1sc1&distro=nx&lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141210005127r1&sid=hq1sc1&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-dr-julie-gerberding-as-executive-vice-president-for-strategic-communications-global-public-policy-and-population-health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"68f75968-8159-4a4f-8643-d9d471125f07","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744873\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744873"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}